Efficacy of Interleukin-2 in Triple Negative Breast Cancer
Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This study is a single arm, non-randomized experimental study design. It will provide us
opportunity to conduct a pilot study to evaluate the efficacy of an intralesional
immunotherapy (e.g. IL-2) in early stage TNBC as a well-tolerated, low-risk intervention with
the potential to improve outcomes without the toxicity of systemic treatment. Following are
the objectives of this study:
1. Utilize new and existing infrastructure within the Breast Health and Women Program at
the IWK to conduct the institutions first surgery-driven breast cancer trial
2. Evaluate the feasibility of patient accrual in a window of opportunity trial design
3. Evaluate the efficacy of intralesional IL-2 to produce a pathologic response in TNBC.
The participants with TNBC will be receiving 3-4 injections of Interleukin-2. Total dose per
injection is 25 million international units per mm width of tumor to max dose of 10 million
IU. Half of total dose will be injected in the center of lesion/tumor and remaining half of
total dose at periphery / peri-tumoral.